India approves Boehringer Ingelheim's Spevigo (Spesolimab) injection for Generalised Pustular Psoriasis flares, marking it as the first-in-class treatment.

India's Central Drugs Standard Control Organisation (CDSCO) approves Boehringer Ingelheim's Spevigo (Spesolimab) injection for adults with Generalised Pustular Psoriasis (GPP) flares, a rare skin disorder. Spevigo is the first-in-class treatment, working by selectively blocking the interleukin-36 receptor (IL-36R) within the immune system. In a global Phase II clinical trial, 54% of GPP patients treated with Spesolimab showed no visible pustules after one week, compared to 6% in the placebo group.